Introduction
============

The colorectal cancer is one of the most frequently diagnosed and deadly cancer globally [@B1]. Nearly 40-50% colorectal cancer patients were initially diagnosed with metastatic lesion(s) [@B2]. Due to distinct outcomes among metastatic colorectal cancer (mCRC) patients, various efforts had been attempted for systematic management. In the clinical practice, the measurement of tumor markers such as carcinoembryonic antigen (CEA), carbohydrate antigen 19-9 (CA19-9) are commonly used during the management of colorectal cancer patients [@B3]. Besides, other readily available indexes associated with the cancer-related metabolism and inflammation processes could be surrogate markers including lactate dehydrogenase (LDH) [@B4], [@B5], neutrophil lymphocyte ratio (NLR) [@B6], [@B7] for evaluating the prognosis. In our previous study, we have also found that increased CEA [@B8], high CA19-9 [@B9], and upraised NLR [@B10] are adverse prognostic indicators.

As an encouraging targeting tumor microvascular monoclonal antibody bevacizumab had been widely administrated in mCRC [@B11]-[@B13]. However, as the angiogenesis process in mCRC is not completely discerned, the optimal predictive factor for bevacizumab has not been discovered yet [@B14], [@B15]. Our earlier study suggested that the LDH in peripheral blood would serve as a potential predictor of bevacizumab therapy [@B16]. Nonetheless, the several isoforms could hardly make LDH a satisfactory biomarker candidate.

The objective of our present study was to assess the association of baseline serum CEA, CA 19-9, LDH, and NLR with outcomes of mCRC patients and bevacizumab effect.

Materials and Methods
=====================

Patients
--------

We retrospectively analyzed the intact data of 284 patients who were pathological diagnosed with mCRC and with clinical and/or pathological confirmations of metastasis at Sun Yat-Sen University Cancer Center from January 2005 to March 2014 and finished the integrated course of first-line treatment in this center. Patients in chemotherapy plus bevacizumab group received more than 4 cycles bevacizumab (at a dose of 5 mg/kg on day 1) [@B17] was administered as a combination with the standard oxaliplatin-based or irinotecan-based first-line chemotherapy. None of the patients had previously or subsequently received other target therapies. Patients who lack of a pathological diagnosis or complete medical history, loss to follow-up, suffering from two or more kinds of tumors asynchronously or synchronously were excluded.

Laboratory measurement, calculation and grouping
------------------------------------------------

Neutrophil and lymphocyte counts were contained in complete blood counts test by the Sysmex XE-5000™ Automated Hematology System (Shanghai, China). NLR was calculated as neutrophil count (number of neutrophils ×10^9^/L) divided by lymphocyte count (number of lymphocytes ×10^9^/L), using the median value 2.47 for cutoff. While LDH was contained in biochemical test by the Hitachi Automatic Analyzer 7600-020 (Tokyo, Japan). Roche Elecsys 2010 Chemistry Analyzer (Basel, Switzerland) was used to test CEA and CA19-9. The upper normal values were used as cutoff: CEA 5 ng/ml; CA 19-9 35 ng/ml; LDH 245 U/ml.

Follow up and statistical analysis
----------------------------------

The latest follow-up was performed on June 30ed, 2016 through telephone interview or medical records review. Overall survival (OS) was measured from date of diagnosis with mCRC to the date of death. Progression free survival (PFS) was measured from the initiation of first line therapy to the progression. Both OS and PFS were estimated by the Kaplan-Meier method and survival differences were analyzed by the log-rank test. The distributions of the baseline characteristics of the patients were assessed by the χ2 test. The P value less than 0.05 was considered with statistically significant.

Human Rights
------------

The protocol of our study was approved by the independent ethics committee of the Sun Yat-Sen University Cancer Center and complied with the International Ethical Guidelines for Biomedical Research Involving Human Subjects, Good Clinical Practice guidelines, the Declaration of Helsinki, and local laws. Written informed consent was gathered from each patient.

Results
=======

Patient characteristics
-----------------------

A total of 284 patients were enrolled in this retrospective study, including 59 patients received chemotherapy containing bevacizumab (B+C group) and 225 patients received chemotherapy alone (C group). The patient characteristics between the two groups are shown in Table [1](#T1){ref-type="table"}. All of the factors were balanced in statistics. As a main clinic parameter, the bevacizumab treatment was separately statistically compared, making it difficult to judge whether these two groups were comparable according to initial levels of serum indexes (Table [2](#T2){ref-type="table"}). The bevacizumab administrations were balanced within different subgroup of several serum indexes.

Relation between initial levels of serum indexes and survival
-------------------------------------------------------------

Initial serum levels of CEA, CA 19-9, LDH, and NLR are shown in Table [3](#T3){ref-type="table"}. The median PFS and OS for patients with low CEA was 12.0 and 33.7 months compared to 9.1 and 25.5 months for patients with high CEA (*P* = 0.002 and *P* = 0.008) (Figure [1](#F1){ref-type="fig"}A, B). The median PFS and OS for patients with low CA 19-9 was 11.4 and 35.7 compared to 7.9 and 22.3 months for patients with high CA 19-9 (*P* \< 0.001 and *P* \< 0.001) (Figure [2](#F2){ref-type="fig"}A, B). The median PFS and OS for patients with low LDH was 10.8 and 33.0 compared to 8.2 and 19.5 months for patients with high LDH (*P* \< 0.001 and *P* \< 0.001) (Figure [3](#F3){ref-type="fig"}A, B). The median PFS and OS for patients with low NLR was 10.8 and 32.6 compared to 8.2 and 22.4 months for patients with high NLR (*P* = 0.002 and *P* = 0.001) (Figure [4](#F4){ref-type="fig"}A, B).

All the prognostic serum factors were assessed together in multivariate Cox proportional hazards model. The multivariate Cox proportional hazards model revealed that the CA19-9 (*HR* = 1.45,*P* = 0.004), LDH (*HR* = 1.37,*P* = 0.04) were significantly associated with PFS, and the CA19-9 (*HR* = 1.60, *P* = 0.01), LDH (*HR* = 1.84, *P* \< 0.001), NLR (*HR* = 1.38,*P* = 0.04) were significantly associated with OS (Table [4](#T4){ref-type="table"}).

Relation between initial levels of serum indexes and bevacizumab efficacy
-------------------------------------------------------------------------

On the basis of whether the first line therapy containing bevacizumab or not, the patients could be further divided into bevacizumab plus chemotherapy (B+C group) and chemotherapy group (C group). In the high CA19-9 subgroup, patients had favorable OS from bevacizumab treatment in the first line (32.1 vs. 20.1 months,*P* = 0.03, Figure [5](#F5){ref-type="fig"}A), though without progression free survival benefit (10.6 vs. 7.2 months,*P* = 0.07, Figure [5](#F5){ref-type="fig"}B). When it comes to low CA19-9 subgroup, CEA, LDH, and NLR subgroups, there were no statistically survival difference between B+C group and C group (Table [5](#T5){ref-type="table"}).

Discussion
==========

Bevacizumab, the classical anti-angiogenesis drug, had been widely applied in various cancers [@B18]. Meanwhile, hunting for suitable predictor of bevacizumab efficacy continues. Several surrogates including circulating vascular endothelial growth factor A (VEGF-A) isoforms, vascular endothelial growth factor receptor-1,2 (VEGFR-1, and VEGFR-2) had been explored but not sufficiently validated for routine clinical use[@B15], [@B19]. CEA, CA19-9, LDH, NLR are readily available serum biomarkers in diagnosing and monitoring the mCRC patients. Therefore, we paid attention to the correlation between these indexes and bevacizumab efficacy.

As an intercellular adhesion molecular of immunoglobulin superfamily, CEA promotes the gathering of tumor cells [@B20]. It is reported CEA had a specificity of 90% and a sensitivity of 40% to 75% in colorectal cancer [@B3]. Albeit CEA is a widely accepted prognostic biomarker in colorectal cancer [@B21], [@B22], it is still dubious in several other studies [@B23]-[@B25] in which CEA showed no statistically significant prognostic value. In our study, we found a significantly shorter PFS and OS in patients with high initial CEA levels. However, it did not prove to be an independent biomarker in the multivariate Cox proportional hazards model. Moreover, there was no association between baseline CEA levels and the efficacy of bevacizumab based therapy.

Though CA19-9 frequent elevation caused by pancreatitis, obstructive jaundice and pancreatic cancer [@B26], it\'s still a critical additional marker to monitor colorectal cancer [@B27]. Almost 35% to 40% of colorectal cancer patients had increased CA19-9 level [@B28]. CA19-9 had been found promoting adhesion of cancer cells to endothelial [@B29]. Similarly, we observed high initial CA19-9 level associated with a significantly poor PFS and OS, and the multivariate Cox proportional hazards model confirmed that CA 19-9 was independent prognostic marker. On the other hand, several studies [@B30]-[@B32] have reported that patients received bevacizumab plus chemotherapy have promising OS compared with chemotherapy alone in the high pre-treatment CA19-9 level group. While there was no similar difference in normal CA19-9 group. Fiala O *et al.* [@B33] had observed the analogous results among patients with bevacizumab treatment. Likewise, our data indicated the potential predictive role of CA19-9 in bevacizumab therapy.

LDH, the main catalyst of aerobic glycolysis, reflects the metabolic status of tumor cells. High serum LDH level had been demonstrated to be a unfavorable prognostic factor in several tumors [@B34]-[@B36]. Our previous study has also explored the associated of the serum LDH, the outcome and the bevacizumab efficacy [@B16]. In our present study, the lack of correlation between serum LDH and bevacizumab efficacy, may enlighten the further exploration of local LDH in tumor microenvironment.

Increased NLR was associated with poor tumor outcome had been observed before [@B10], [@B37], implying the interaction of inflammatory and immune response play a role in tumor progression. Our data here is consistent with this conclusion.

The main limitations of this study are its retrospective design and relatively small number of patients with bevacizumab therapy.

In conclusion, the initial CA19-9, LDH level were independently associated with PFS, while the baseline CA19-9, LDH, and NLR level independently associated with OS in first line treatment. The pre-treatment CA19-9 level could potentially serve as a predictor of bevacizumab. Prospective studies on the predictive role of serum markers should be conducted to certify the results.
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###### 

Patient characteristics

  Characteristics                   *n* (%, total n=284)
  --------------------------------- ----------------------
  Males                             187 (65.8)
  Age (years)                       
  median, range                     55 (19-87)
  ≤60                               191 (67.3)
  \>60                              93 (32.7)
  Primary Tumor                     
  Right colon                       87 (30.6)
  Left colon                        95 (33.5)
  Rectum                            102 (35.9)
  Pathological type                 
  Well differentiation              3 (1.1)
  Moderately differentiation        177 (63.3)
  Poorly differentiation            64 (22.5)
  Mucinous adenocarcinoma           35 (12.3)
  Unknown ^a^                       5 (1.8)
  Pathologic tumor classification   
  T1                                4 (1.4)
  T2                                9 (3.2)
  T3                                50 (17.6)
  T4                                219 (77.1)
  Unknown ^b^                       2 (0.7)
  Lymphatic invasion                201 (70.8)
  Vascular invasion                 26 (9.2)
  Perineural invasion               8 (2.8)
  First line bevacizumab therapy    
  With Bevacizumab                  59 (20.8)
  Without Bevacizumab               225 (79.2)
  First line chemotherapy regimen   
  Oxaliplatin-based                 213 (75.0)
  Irinotecan-based                  53 (18.7)
  Fluorouracil alone                5 (1.8)
  Oxaliplatin plus irinotecan       13 (4.5)

^a^ This part of patients was pathological diagnosed with colorectal adenocarcinoma without the differentiation degree by the biopsy specimen or pathology consultation of specimen from other hospitals; ^b^ There were no surgical primary tumor specimen of these patients.

###### 

Statistically comparison of bevacizumab treatment according to initial levels of serum indexes

  ----------------------------------------------------------------------
                       With bevacizumab\   Without bevacizumab\   *P*
                       *n*(%)              *n* (%)                
  -------------------- ------------------- ---------------------- ------
  **CEA (ng/ml)**                                                 0.87

  **≤5**               15 (19.5)           62 (80.5)              

  **\>5**              44 (21.3)           163 (78.7)             

  **CA19-9 (ng/ml)**                                              0.77

  **≤35**              30 (21.7)           108 (78.3)             

  **\>35**             29 (19.9)           117 (80.1)             

  **LDH (U/ml)**                                                  0.94

  **≤245**             43 (20.7)           165 (79.3)             

  **\>245**            16 (21.1)           60 (78.9)              

  **NLR**                                                         0.55

  **≤2.47**            29 (20.7)           111 (79.3)             

  **\>2.47**           30 (20.8)           114 (79.2)             
  ----------------------------------------------------------------------

CEA carcinoembryonic antigen, CA 19-9 carbohydrate antigen 19-9, LDH lactate dehydrogenase, NLR neutrophil lymphocyte ratio

###### 

Progression free survival and overall survival according to initial levels of serum indexes

                   n (%)        median PFS (months, 95%*CI*)   *P*       median OS (months, 95%*CI*)   *P*
  ---------------- ------------ ------------------------------ --------- ----------------------------- ---------
  CEA (ng/ml)                                                  0.002                                   0.008
  ≤5               77 (27.1)    12.0 (9.6-14.4)                          33.7 (26.9-40.5)              
  \>5              207 (72.9)   9.1 (8.0-10.2)                           25.5 (21.6-29.4)              
  CA19-9 (ng/ml)                                               \<0.001                                 \<0.001
  ≤35              102 (35.9)   11.4 (9.6-13.3)                          35.7 (30.5-40.9)              
  \>35             118 (41.1)   7.9 (6.6-9.3)                            22.3 (18.0-26.5)              
  LDH (U/ml)                                                   \<0.001                                 \<0.001
  ≤245             208 (73.3)   33.0 (28.9-37.2)                         10.8 (9.3-12.3)               
  \>245            76 (26.7)    19.5 (16.0-23.0)                         8.2 (6.7-9.8)                 
  NLR                                                          0.002                                   0.001
  ≤2.47            140 (49.3)   10.8 (9.3-12.3)                          32.6 (29.7-35.5)              
  \>2.47           144 (50.7)   8.2 (6.9-9.6)                            22.4 (18.6-26.3)              

CEA carcinoembryonic antigen, CA 19-9 carbohydrate antigen 19-9, LDH lactate dehydrogenase, NLR neutrophil lymphocyte ratio, PFS progression free, OS overall survival, *CI* confidence interval

###### 

Hazard ratios from multivariate Cox proportional hazard model for progression free survival and overall survival

  Index    PFS                OS                         
  -------- ------------------ ------- ------------------ ---------
  CEA      1.23 (0.91-1.67)   0.12    1.05 (0.75-1.45)   0.8
  CA19-9   1.45 (1.12-1.88)   0.004   1.60 (1.21-2.13)   0.001
  LDH      1.37 (1.02-1.84)   0.04    1.84 (1.35-2.50)   \<0.001
  NLR      1.27 (0.96-1.68)   0.1     1.38 (1.01-1.87)   0.04

CEA carcinoembryonic antigen; CA 19-9 carbohydrate antigen 19-9, LDH lactate dehydrogenase, NLR neutrophil lymphocyte ratio, PFS progression free, OS overall survival, HR hazard ratio, *CI* confidence interval

###### 

Association of bevacizumab efficacy and initial levels of serum indexes

                   median PFS (months, 95%*CI*)   *P*              median OS (months, 95%*CI*)   *P*                                 
  ---------------- ------------------------------ ---------------- ----------------------------- ----------------- ----------------- --------
  CEA (ng/ml)                                                                                                                        
  ≤5               16.4(8.8-24.0)                 12.0(9.0-15.0)   0.4                           46.5(25.2-67.9)   33.7(26.4-41.0)   0.9
  \>5              10.6(10.0-11.1)                8.2(7.0-9.4)     0.3                           29.6(22.6-36.6)   24.6(20.7-28.5)   0.2
  CA19-9 (ng/ml)                                                                                                                     
  ≤35              12.8(7.8-17.8)                 11.2(8.9-13.5)   0.80                          36.9(31.7-42.2)   30.3(8.6-52.0)    0.70
  \>35             10.6(8.4-12.7)                 7.2(6.4-8.0)     0.07                          32.1(24.8-39.4)   20.1(15.8-24.4)   *0.04*
  LDH (U/ml)                                                                                                                         
  ≤245             12.2(10.1-14.3)                9.4(7.3-11.5)    0.4                           39.9(24.0-55.8)   32.3(27.8-36.9)   0.4
  \>245            8.3(6.0-10.7)                  8.0(6.0-9.9)     0.3                           20.1(17.1-23.1)   17.5(12.6-22.4)   0.7
  NLR                                                                                                                                
  ≤2.47            12.8(9.0-16.6)                 9.8(8.3-11.3)    0.4                           34.0(22.3-45.6)   32.3(29.2-35.4)   0.8
  \>2.47           10.4(8.8-12.0)                 7.8(6.8-9.0)     0.4                           23.4(14.8-32.0)   21.5(16.5-26.6)   0.2

CEA carcinoembryonic antigen, CA 19-9 carbohydrate antigen 19-9, LDH lactate dehydrogenase, NLR neutrophil lymphocyte ratio, PFS progression free, OS overall survival, *CI* confidence interval, C chemotherapy, B+C bevacizumab plus chemotherapy
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